APTEVO THERAPEUTICS INC (APVO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.74+1.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · APVO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue Phase 1b/2 RAINIER trial dose optimization and prepare for Phase 2 regulatory interaction in early 2027.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and a recent 2026-09-03 release. Mipletamig showed an 87% clinical benefit rate and 81% remission rate across 31 evaluable frontline AML patients. The RAINIER trial dose optimization phase is on track to complete by year-end 2026 with a Phase 2 regulatory interaction planned for early 2027. The clinical data and trial progress indicate management is delivering on this priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Mipletamig continues to lead our value creation strategy, with RAINIER generating compelling frontline AML data and moving toward completion of dose optimization by year end and Phase 2 regulatory in…”
“RAINIER trial on track for completion and Phase 2 dose selection by year end.”
Develop up to three radiopharmaceutical oncology programs through a 50/50 collaboration with Niowave, leveraging isotope supply and cost-sharing.
Stated in 2 quarters including 2026-Q1 and 2026-Q2. Management announced a 50/50 collaboration with Niowave to develop up to three radiopharmaceutical oncology programs, providing access to isotope supply and sharing development costs. The collaboration is recent and ongoing, indicating progress consistent with management's stated strategic expansion.
“Entered a 50/50 collaboration with Niowave that gives us a cost-effective path into radiopharmaceutical therapeutics and access to isotope supply in a constrained market.”
“Advancing radiopharmaceutical collaboration with Niowave to develop up to three oncology programs.”
Progress APVO451 through IND-enabling studies supported by a $1.5 million non-dilutive grant, targeting development candidate selection by year-end 2026.
Stated in 2 quarters including 2026-Q1 and 2026-Q2. Management secured a $1.5 million non-dilutive grant to support IND-enabling studies for APVO451, targeting development candidate selection by year-end 2026. This funding and timeline indicate progress consistent with management's stated development goals.
“Non-dilutive grant funding advances APVO451 and validates trispecific solid tumor strategy.”
“Advancing next generation multispecific immunotherapy programs including trispecific candidates such as APVO451.”
Develop a versatile Nectin-4 x PD-L1 dual-targeting platform to support multiple therapeutic approaches including radiopharmaceuticals and T-cell engagers.
Newly stated in 2026-07-27 press release. Management filed a patent application for a Nectin-4 x PD-L1 dual-targeting backbone to support multiple therapeutic approaches including radiopharmaceuticals and T-cell engagers. This is an early-stage strategic platform development with no financial metrics yet but aligns with management's pipeline expansion goals.
Raise capital to extend financial runway and support clinical and strategic milestones into late 2026 and beyond.
Stated in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Management raised $22.8 million since end of 2Q25, extending financial runway well into 4Q26, with additional $0.9 million and $0.6 million raised under SEPAs in 1Q26 and 2Q26 respectively. These capital raises support management's stated goal of maintaining financial flexibility to fund clinical and strategic milestones, indicating delivery on this priority.
“Raised $0.6 million under Standby Equity Purchase Agreements during 2Q26.”
“Raised $0.9 million net under Standby Equity Purchase Agreements during 1Q26.”
“Raised $22.8 million since end of 2Q25, extending runway well into 4Q26.”
Over the trailing year it converted 1.02x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
26 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.